Operating profit before deduction of amortization: Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals (AUPH) faces risks due to its dependence on Lupkynis and regulatory pressure. The operating profit history in monetary terms on this precise GURU.Markets chart confirms these challenges, where 164.49 reflects the latest metric value. High authority among nephrologists supports the brand, while adherence to basic environmental standards ensures stable compliance during production.
auriniapharma.com (AUPH) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Equity Ratio Aurinia Pharmaceuticals|AUPH - Long-Term Debt to Capital|Current Liabilities to Capital Aurinia Pharma|AUPH - Company Aggregate Debts|Debts to Book Capitalization Aurinia Pharma|AUPH - Company Long-Term Liabilities|Company Short-Term Debts Aurinia Pharmaceuticals|Intermediate Coverage Ratio auriniapharma.com
- earnings and multiples data:
AUPH - Net Profit|Company Profit Forecast Aurinia Pharmaceuticals|AUPH - Price to Earnings Ratio|Price to Future Earnings Ratio Aurinia Pharmaceuticals Inc.|AUPH - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Aurinia Pharmaceuticals Inc.|AUPH - Operating profit EBITDA|Net earnings per share (EPS TTM) Aurinia Pharmaceuticals|AUPH - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months auriniapharma.com|AUPH - Earnings per share growth in current year|Net earnings per share change forecast for next year Aurinia Pharmaceuticals
- sales and revenue indicators:
Summary company analytics:AUPH (Aurinia Pharmaceuticals Inc.)
The market views Aurinia Pharmaceuticals (AUPH) as a promising asset with high scaling potential. This indicator captures operating cash flow before taxes and interest, reflecting the business's actual ability to generate cash. By analyzing absolute EBITDA, investors can see the commercialization efficiency of the drug LUPKYNIS following the completion of costly development stages. The approved product converts revenue into net cash due to a narrow distribution specialization. The asset belongs to the class of high-tech biopharmaceutical securities.
Competitor analysis for Aurinia Pharmaceuticals
Operating income before deduction of amortization argenx.com (ARGX)|BNTX - Profit before payment of interest, taxes and amortization|Abivax Corp (ABVX) - Operating profit before deduction of amortization|ADMA Corp (ADMA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Protagonist Therapeutics|Operating profit before deduction of amortization IMVT|Operating profit EBITDA kiniksa.com|Profit before payment of interest, taxes and amortization Grifols Group (GRFS)|Adaptive Biotechnologies Corporation - Operating profit before amortization|Operating profit EBITDA CLDX (celldex.com)|BioCryst Pharmaceuticals Inc (BCRX) - Profit before interest, taxes and amortization|VERA: Operating profit before deduction of amortization|DNTH (Dianthus Therapeutics) - Operating profit before amortization|PHVS: Operating profit EBITDA|ABCL (AbCellera Biologics Inc.) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization TRML|Profit before interest, taxes and amortization Intrexon PGEN|Profit before payment of interest, taxes and amortization Pharming Group N.V. (PHAR)|Company profit before taxes, interest and amortization NKTR|Operating profit EBITDA UPB (Upstream Pharma)|Operating income before deduction of amortization Zenas Biopharma, Inc. (ZBIO)|IMNM - Profit before payment of interest, taxes and amortization|Gossamer Corp (GOSS) - Operating profit before deduction of amortization|KALV (KalVista Pharmaceuticals Inc) - Operating profit before deduction of amortization|Operating profit before amortization SEPN|Profit before payment of interest, taxes and amortization Pieris Pharmaceuticals|Savara Inc (SVRA) - Operating income before deduction of amortization|Operating profit EBITDA RIGL|Operating income before deduction of amortization AnaptysBio Inc.|Operating profit EBITDA ATXS (Astria Therapeutics Inc)|enGene Holdings Inc. - Profit before payment of interest, taxes and amortization|RAPT - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization JBIO (aerovatetx.com)|Aclaris (ACRS) - Profit before payment of interest, taxes and amortization|Kyverna - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization TLSA|Profit before interest, taxes and amortization Cabaletta Bio CABA|Operating profit EBITDA VTYX|Theratechnologies (THTX) - Operating profit before depreciation charges|Avalo Therapeutics - Operating profit before deduction of amortization|Eledon Pharmaceuticals (ELDN) - Profit before interest, taxes and amortization|Agenus, Inc - Operating profit EBITDA|Profit before interest, taxes and amortization climbbio.com|ZURA (Zura Bio Limited) - Operating profit before deduction of amortization|aTyr (ATYR) - Operating profit EBITDA|Operating profit before deduction of amortization ADAG|IMA: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Shattuck Therapeutics (STTK)|Operating profit before deduction of amortization Equillium EQ|Connect Biopharma Holdings Limited - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization IMUX|ATRA - Profit before payment of interest, taxes and amortization|inflarx.de (IFRX) - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization X4 Pharmaceuticals XFOR|ACET - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization celularity.com|INMB: Income before deduction of interest, taxes and amortization|Operating profit EBITDA BRNS|Operating profit EBITDA Kezar Life Sciences Inc (KZR)|Operating profit EBITDA SABS (SAB Biotherapeutics)|Operating profit EBITDA akaritx.com AKTX|Enlivex Therapeutics Ltd. - Operating profit EBITDA|QTTB - Operating profit EBITDA|GOVX (GeoVax Labs Inc) - Operating profit before deduction of amortization|Operating profit before deduction of amortization Edesa|IBIO (iBio, Inc.) - Operating profit EBITDA|CARM: Income before deduction of interest, taxes and amortization|Operating profit EBITDA XTLB|Operating profit before deduction of amortization Bolt Biotherapeutics, Inc. BOLT|Operating profit EBITDA HCWB (hcwbiologics.com)|Income before deduction of interest, taxes and amortization APVO|AIM ImmunoTech, Inc. - Operating profit EBITDA|ADTX (Aditxt Inc.) - Operating profit before amortization|GRI: Operating profit EBITDA|Operating profit before deduction of amortization XORTX Therapeutics|Operating profit before deduction of amortization HIND|REVB: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization indaptusrx.com (INDP)|Operating profit before deduction of amortization Scinai Immunotherapeutics SCNI|Operating profit EBITDA CALI (CalciMedica Inc)|AFMD: Operating profit before amortization|ALLK - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization hookipapharma.com|IGMS: Operating profit EBITDA|ITOS: Company profit before taxes, interest and amortization|OCEA (Ocean Biomedical Corp) - Operating profit EBITDA|TCBP: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Third Harmonic Bio, Inc (THRD)
